News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease



11/7/2007 11:17:01 AM

TOKYO--(BUSINESS WIRE)--GNI Ltd, a leading biopharmaceutical company in Japan and China, is pleased to announce that China’s Patent & Trademark Office has granted Shanghai Genomics, GNI’s wholly owned China subsidiary, regional patent rights relating to one of its lead drug candidates, F351 and its use (China Patent ZL 200380110691.0). This patent is a part of the Company’s global patent portfolio and provides protection for an important piece of its intellectual property in China.

Read at BioSpace.com


comments powered by Disqus
GNI
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES